Onyx Biotec Limited
Bookbuilding IPO · NSE
- Price band
- ₹58 - ₹61
- Lot size
- 2,000 shares
- Issue amount
- ₹29.34 cr
- Total subscription
- 198.68×
- Opens
- 11 Nov 2024
- Closes
- 18 Nov 2024
- Allotment
- 19 Nov 2024
- Listing
- 22 Nov 2024
Offer at a glance
Issue overview
- Issue size
- 48,10,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,16,000
- Fresh issue
- ₹29.34 cr
- Offer for sale
- ₹0 cr
- Registrar
- Mas Services Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,22,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 1,33,22,200
- Shares after issue
- 1,81,32,200
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 2,000 | ₹1,22,000 |
| HNI | 2 | 4,000 | ₹2,44,000 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | — | 22 |
| NIB | — | 9,351 |
| RETAIL | — | 95,489 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 5.56 | 180.77 |
| RETAIL | 9.76 | 1,164.97 |
| HNIs 2+ | 0 | 0 |
| HNIs 10+ | 0 | 0 |
| EMPLOYEES | 0 | 0 |
| Shareholder | 0 | 0 |
Financial performance
Company financials
In Lakhs. · Reported periods may include interim results.
Key performance indicators
| Metric | May-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 0.98 | 2.54 | 1.56 |
| ROE | 4.99 | 12.19 | 10.13 |
| ROCE | 3.71 | 10.58 | 6.29 |
| RONW | 4.99 | 12.19 | 10.13 |
| PRE IPO(PE) | 26.81 | 0 | 0 |
| POST IPO(PE) | 14.1 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company focused on producing sterile water for injections and offering contract manufacturing services. It operates two facilities in Solan, Himachal Pradesh, where Unit I makes up to 6.38 lakh units of sterile water injections daily, and Unit II manufactures 40,000 units of dry powder injections and 26,667 units of dry syrup per day. The company caters to both domestic and international markets and serves over 100 clients, including well-known names like Hetero Healthcare, Mankind Pharma, Sun Pharma, and Reliance Life Sciences. Onyx Biotec is ISO 9001:2015 and ISO 14001:2015 certified and employed 175 people as of July 31, 2024.
Strengths
- Expertise in Sterile Manufacturing: Recognized as a leading contract manufacturer with specialization in sterile formulations, delivering high-standard products in a highly regulated domain.
- Strong Quality Systems: Maintains robust quality assurance and quality control frameworks to ensure consistent product safety, compliance, and performance.
- Established Client Relationships: Long-standing partnerships with reputed clients drive repeat business and ensure stable revenue visibility.
Risk factors
- Regional Concentration: All manufacturing units are located in Solan, Himachal Pradesh, exposing operations to region-specific economic, political, and natural disruptions that could halt production.
- Operational Disruptions: Any slowdown or shutdown at the facilities may materially impact business continuity, financial performance, and cash flows.
- Quality & Delivery Challenges: Quality lapses or delays in product delivery may lead to order cancellations, contract breaches, reputational damage, and loss of client trust, thereby impacting future revenues.
Promoters
Sanjay Jain
Naresh Kumar
Fateh Pal Singh
Registrar & documents
Lead manager
Horizon Management private Limited
Registrar & contacts
Mas Services Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Bir Plassi Near Sainimajraropar, Nalagarh Road District Solan - 174101
+91 1722656384
[email protected]Company website ↗Understanding ONYX1 IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.